Preparation method of extremely small embryonic-like stem cells
By employing methods of isolation and culture medium optimization, the problems of scarce numbers and low isolation and purification efficiency of minimal embryonic stem cells have been solved, enabling efficient cell preparation and passage, and providing a stable cell source for myocardial regeneration research.
Patent Information
- Application Number
- CN202411261736.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-10
- Publication Date
- 2024-11-29
AI Technical Summary
Existing technologies for extremely small embryonic stem cells are scarce, and the isolation and purification techniques are complex and inefficient, which cannot meet the needs of myocardial regeneration research.
Bone marrow mononuclear cells were isolated using specific steps, tiny embryonic-like stem cells were sorted using fluorescently labeled antibodies, and cultured in optimized complete culture media, including DMEM-F12 medium and a combination of various growth factors and inhibitors, while controlling the use of digestive enzymes and inoculation density.
It significantly improved the survival rate and purity of minimal embryonic stem cells, optimized cell culture conditions, and achieved efficient cell preparation and passage, providing a stable cell source for myocardial regeneration research.
Smart Images

Figure SMS_1
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of cell culture, and in particular to a method for preparing extremely small embryonic-like stem cells. Background Art
[0002] Cardiovascular disease causes approximately 12 million deaths each year, accounting for nearly a quarter of the total global death toll, and is one of the greatest threats to human health. For diseases such as myocardial infarction or heart failure, traditional therapies such as drug therapy, interventional therapy, and surgery are unable to regenerate missing cardiomyocytes, leading to irreversible myocardial remodeling, which may eventually lead to heart failure and death. In recent years, stem cell regenerative medicine has made important progress in the treatment of cardiovascular diseases, especially through cellular cardiomyoplasty, which is the transplantation of stem cells or cardiomyocytes, or the mobilization of stem cells in peripheral blood or bone marrow to migrate to damaged myocardial areas to repair damage.
[0003] At present, the stem cells used in experiments mainly include embryonic stem cells (ESCs) and adult stem cells. Because embryonic stem cells involve immune rejection and ethical issues, they are limited in clinical application. In contrast, adult stem cells, especially bone marrow-derived stem cells, are considered to be the most promising type of cell transplantation because they do not have immune rejection problems and are easy to collect. Adult stem cells include but are not limited to hematopoietic stem cells, bone marrow mononuclear cells, bone marrow mesenchymal stem cells, endothelial progenitor cells, skeletal muscle myoblasts, umbilical cord blood stem cells, and adipose-derived stem cells. Mechanism of stem cell therapy Stem cell transplantation can increase the release of cytokines such as vascular endothelial growth factor (VEGF), promote new blood vessel formation in ischemic areas, improve blood perfusion, and help restore the function of hibernating and stunned myocardium, reducing ventricular dilation and remodeling. Transplanted stem cells can differentiate into cardiomyocytes, vascular endothelial cells, and smooth muscle cells under the induction of the local microenvironment, but some studies have also pointed out that transplanted bone marrow stem cells do not differentiate into cardiomyocytes, but differentiate into other types of blood cells. Therefore, the lateral differentiation potential of adult stem cells has become a hot topic of research. Very small embryonic stem cells (VSELs) In recent years, researchers have discovered stem cells similar to embryonic stem cells in adult tissues - very small embryonic stem cells (VSELs), which have true lateral differentiation potential.
[0004] The characteristics of VSELs include (1) rare number: accounting for about 0.01-0.02% of bone marrow mononuclear cells (MNCs), and decreasing with age; (2) pluripotency markers: Sca-1 positive / Lineage negative / CD45 negative in mice, CD133 positive / CXCR4 positive / CD34 positive / Lin negative / CD45 negative in humans. (3) Morphological characteristics: small size, with a diameter of about 2-4 μm (mice) and 6-8 μm (humans), with large nuclei, thin cell walls, high nuclear / cytoplasmic ratio and other typical characteristics of embryonic stem cells. VSELs are widely present in multiple tissues and organs, such as bone marrow, brain, kidney, muscle, pancreas, as well as umbilical cord blood, bone marrow and peripheral blood. After acute myocardial infarction, the number of VSELs increases significantly and is mobilized into peripheral blood. This process is related to the upregulation of multiple chemokines such as SDF-1. Under appropriate induction conditions, VSELs can differentiate into cells derived from the three germ layers, including cardiomyocytes. The discovery of VSELs not only provides a new stem cell resource for myocardial regeneration, but more importantly, they have similar lateral differentiation potential and surface antigen markers as embryonic stem cells, but do not have the immune rejection and ethical issues brought about by embryonic stem cells.
[0005] Therefore, there is an urgent need for a method for preparing extremely small embryonic-like stem cells to solve the problems existing in the existing technology and open up a new direction for the research on stem cell regeneration of myocardium. Summary of the invention
[0006] To this end, the present invention provides a method for preparing very small embryonic-like stem cells to solve the problems in the prior art that the number of very small embryonic-like stem cells is extremely rare, and the separation and purification technology is complex and inefficient.
[0007] In order to achieve the above object, the present invention provides the following technical solutions: According to a first aspect of the present invention, a method for preparing very small embryonic-like stem cells comprises the following steps: S1. Extract mouse femurs under sterile conditions and wash to obtain bone marrow stock solution, then filter, centrifuge, separate mononuclear cells, lyse red blood cells, centrifuge again and resuspend to obtain mononuclear cell suspension; S2. resuspending, labeling, incubating, washing and sorting the bone marrow mononuclear cell solution obtained in S1 to obtain SMEL stem cells; S3. The sorted VSELs were inoculated into T225 culture flasks, complete medium was added, and the cells were cultured until the cell confluence reached 85%, and then washed, digested, and digested. The cells after digestion were collected to obtain P0 VSELs. S4. The P0 generation VSEL stem cells are inoculated into a T225 culture flask, complete culture medium is added, and culture is continued. During the culture process, the medium is changed every 2 days until the cell fusion rate reaches 90%, and then the P1 generation VSEL stem cells are obtained.
[0008] Furthermore, the complete culture medium uses DMEM-F12 culture medium as the base liquid, and includes the following components at the following concentrations: Epidermal growth factor 1ng / mL, ActivinA 1ng / mL, transforming growth factor β 2ng / mL, transforming growth factor α ng / mL, vascular endothelial growth factor 2ng / mL, basic fibroblast growth factor 50ng / mL, MEK inhibitor 0.1μM, GSK-3 inhibitor 30μM, leukemia inhibitory factor 3ng / mL, ALK-5 inhibitor A83-01 50μM, dasatinib 0.001μM, interleukin-1β 10ng / mL, interleukin-6 ng / mL, fibronectin 5mg / L, laminin 3mg / L, transferrin 5mg / L, sodium bicarbonate 2.5g / L, estradiol 3ng / mL, human serum albumin 20ng / mL, insulin 5mg / L, L-glutamine 285.3mg / L, α-D-glucose 3135mg / L, vitamin C 80mg / L, CuSO4 20ng / mL, ZnSO4 100ng / mL, Na2SeO30.01ng / mL, FeCl3 200ng / mL, Na2SiO3 100ng / mL, MnSO4 20ng / mL, CoCl2 20ng / mL.
[0009] Furthermore, the separation of S1 bone marrow mononuclear cells comprises the following specific steps: S11. After extracting the mouse femur under sterile conditions, the femur was rinsed with PBS buffer solution to obtain bone marrow stock solution, and the bone marrow stock solution was mixed with heparin saline; S12. Filter the cells using a 50 μm filter and centrifuge at 1400-600 rpm for 5-10 min at 4°C; S13. Remove the supernatant, mix the cell pellet with Lymphoprep separation solution, aspirate the middle white layer rich in mononuclear cells, add red blood cell lysis solution at a volume ratio of 1:5, lyse for 3-5 minutes in an ice bath, and then add 20mL PBS to terminate the reaction; S14. Centrifuge again at 4°C at a speed of 1400-600 rpm for 5-20 min, discard the supernatant, and add PBS containing 2 mM EDTA and 3% FBS to the precipitate to make up to 350 μL to resuspend the cells.
[0010] Furthermore, in S2, the specific steps of mononuclear cell labeling and SMES sorting are as follows: S21. The bone marrow mononuclear cell solution obtained in S14 was resuspended in a buffer solution, and 10% FCS was added. The suspension was placed in an ice bath for 20 min, and then centrifuged at 4°C at a speed of 1400-600 rpm for 5-20 min. S22. Discard the supernatant, add buffer, mix thoroughly, and prepare 6 Falcon tubes, including 1 isotype control staining tube, 4 single staining tubes, and 1 cell sorting tube; Three fluorescently labeled antibodies were added to the sorting cell tube: PE-labeled Lineage antibody mixture, PE-Cy5-labeled CD45 monoclonal antibody, and FITC-labeled Sca-1 monoclonal antibody; three corresponding isotype control antibodies were added to the isotype control staining tube; The 4 single staining tubes are: the first single staining tube is added with PE-labeled Lineage antibody mixture and the other two isotype control antibodies; the second single staining tube is added with PE-Cy5-labeled CD45 monoclonal antibody and the other two isotype control antibodies; the third single staining tube is added with FITC-labeled Sca-1 monoclonal antibody and the other two isotype control antibodies; the fourth single staining tube is added with another fluorescent labeled antibody (APC-labeled antibody) and the other two isotype control antibodies; Vortex to mix thoroughly, incubate in an ice bath in the dark for 15 min; S23. Wash with 2% FCS / PBS containing 2 mM EDTA, centrifuge, remove the supernatant, resuspend in 2% FCS / PBS, sort on Moflo XDP cell sorter, set Lin - Sca-1 + CD45 - The cell population is very small embryonic stem cells.
[0011] Furthermore, the heparin sodium concentration of the heparin saline is 3000-10000 U / mL; and the volume ratio of the bone marrow stock solution to the heparin saline is 3:2-9.
[0012] Furthermore, the density of the Lymphoprep separation solution is 1.077 g / mL, and the volume ratio of the cell precipitation to the Lymphoprep separation solution is 1:1-5.
[0013] Furthermore, 5-15 mL of complete culture medium is added to S3, and 18-24 mL of complete culture medium is added to S4.
[0014] Furthermore, in S3, a recombinant pancreatic enzyme solution is used for digestion, the digestion time is 3 minutes, and the concentration of pancreatic enzyme in the recombinant pancreatic enzyme solution is 0.25-2.5 g / L.
[0015] Furthermore, the inoculation density in S4 is 3000-10000 cells / cm 2 .
[0016] Furthermore, the culture conditions in S4 are culture in an incubator at 37° C. and 5% CO 2 .
[0017] The present invention has the following advantages: 1. The synergistic effect of various growth factors and inhibitors in the complete culture medium provides the best growth environment for cells, helps maintain the pluripotency and proliferation ability of cells, and at the same time, by providing essential nutrients and growth signals, the complete culture medium helps to improve the survival rate of cells and reduce the loss of cells during the culture process. The precise ratio of various components in the complete culture medium optimizes the cell culture conditions and improves the overall efficiency and success rate of cell culture.
[0018] 2. Through precise cell separation, labeling and sorting steps, as well as optimized complete culture medium formula, the survival rate and purity of very small embryonic-like stem cells are significantly improved.
[0019] 3. By comprehensively controlling the composition of complete culture medium, the use of digestive enzymes, inoculation density and other parameters, the cell culture conditions were optimized, the overall efficiency of cell culture was improved, and the efficient culture and passaging of VSELs was achieved, providing a stable cell source for the research and application of VSELs and promoting the maintenance of cell proliferation and differentiation potential. DETAILED DESCRIPTION
[0020] The following is a description of the implementation of the present invention by specific embodiments. People familiar with the art can easily understand other advantages and effects of the present invention from the contents disclosed in this specification. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0021] The present invention provides a method for preparing very small embryonic-like stem cells, comprising the following steps: S1. Extract mouse femurs under sterile conditions and wash to obtain bone marrow stock solution, then filter, centrifuge, separate mononuclear cells, lyse red blood cells, centrifuge again and resuspend to obtain mononuclear cell suspension; S2. resuspending, labeling, incubating, washing and sorting the bone marrow mononuclear cell solution obtained in S1 to obtain SMEL stem cells; S3. The sorted VSELs were inoculated into T225 culture flasks, complete medium was added, and the cells were cultured until the cell confluence reached 85%, and then washed, digested, and digested. The cells after digestion were collected to obtain P0 VSELs. S4. Inoculate the P0 generation VSEM into a T225 culture flask, add complete culture medium, and continue culturing. Change the medium every 2 days during the culture process until the cell fusion rate reaches 90%. Then, subculture to obtain the P1 generation VSEM.
[0022] Specifically, the complete culture medium uses DMEM-F12 culture medium as the base liquid, and includes the following components at the following concentrations: Epidermal growth factor (EGF) 1ng / mL, ActiviA 1ng / mL, transforming growth factor β 2ng / mL, transforming growth factor α 1ng / mL, vascular endothelial growth factor (VEGF) 2ng / mL, basic fibroblast growth factor 50ng / mL, MEK inhibitor PD0325901 0.1μM, GSK-3 inhibitor CHIR99021 30μM, leukemia inhibitory factor 3ng / mL, ALK-5 inhibitor A83-01 50μM, dasatinib 0.001μM, interleukin-1β 10ng / mL, interleukin-6 ng / mL, fibronectin 5mg / L, laminin 3mg / L, transferrin 5mg / L, sodium bicarbonate 2.5g / L, estradiol 3ng / mL, human serum albumin 20ng / mL, insulin 5 mg / L, L-glutamine 285.3mg / L, α-D-glucose 3135 mg / L, vitamin C 80mg / L, CuSO4 20ng / mL, ZnSO4 100ng / mL, Na2SeO3 0.01ng / mL, FeCl3 200ng / mL, Na2SiO3 100ng / mL, MnSO4 20ng / mL, CoCl2 20ng / mL.
[0023] Specifically, the isolation of S1 bone marrow mononuclear cells includes the following specific steps: S11. After extracting the mouse femur under sterile conditions, the femur was rinsed with PBS buffer solution to obtain bone marrow stock solution, and the bone marrow stock solution was mixed with heparin saline; S12. Filter the cells using a 50 μm filter and centrifuge at 1400-600 rpm for 5-10 min at 4°C; S13. Remove the supernatant, mix the cell pellet with Lymphoprep separation solution, aspirate the middle white layer rich in mononuclear cells, add red blood cell lysis solution at a volume ratio of 1:5, lyse for 3-5 minutes in an ice bath, and then add 20mL PBS to terminate the reaction; S14. Centrifuge again at 4°C at a speed of 1400-600 rpm for 5-20 min, discard the supernatant, and add PBS containing 2 mM EDTA and 3% FBS to the precipitate to make up to 350 μL to resuspend the cells.
[0024] 4. According to the method for preparing SMEL stem cells according to claim 1, in S2, the specific steps of mononuclear cell labeling and SMEL stem cell sorting are as follows: S21. The bone marrow mononuclear cell solution obtained in S14 was resuspended in a buffer solution, and 10% FCS was added. The suspension was placed in an ice bath for 20 min, and then centrifuged at 4°C at a speed of 1400-600 rpm for 5-20 min. S22. Discard the supernatant, add buffer, mix thoroughly, and prepare 6 Falcon tubes, including 1 isotype control staining tube, 4 single staining tubes, and 1 cell sorting tube; Three fluorescently labeled antibodies were added to the sorting cell tube: PE-labeled Lineage antibody mixture, PE-Cy5-labeled CD45 monoclonal antibody, and FITC-labeled Sca-1 monoclonal antibody; three corresponding isotype control antibodies were added to the isotype control staining tube; The 4 single staining tubes are: the first single staining tube is added with PE-labeled Lineage antibody mixture and the other two isotype control antibodies; the second single staining tube is added with PE-Cy5-labeled CD45 monoclonal antibody and the other two isotype control antibodies; the third single staining tube is added with FITC-labeled Sca-1 monoclonal antibody and the other two isotype control antibodies; the fourth single staining tube is added with another fluorescent labeled antibody (APC-labeled antibody) and the other two isotype control antibodies; Vortex to mix thoroughly, incubate in an ice bath in the dark for 15 min; S23. Wash with 2% FCS / PBS containing 2 mM EDTA, centrifuge, remove the supernatant, resuspend in 2% FCS / PBS, sort on Moflo XDP cell sorter, set Lin - Sca-1 + CD45 - The cell population is very small embryonic stem cells.
[0025] Specifically, the heparin sodium concentration of the heparin saline is 3000-10000-12000 U / mL; the volume ratio of the bone marrow stock solution to the heparin saline is 3:2-9.
[0026] Specifically, the density of Lymphoprep separation solution is 1.077 g / mL, and the volume ratio of cell precipitation to Lymphoprep separation solution is 1:1-5.
[0027] Specifically, 5-15 mL of complete culture medium is added to S3, and 18-24 mL of complete culture medium is added to S4.
[0028] Specifically, in S3, recombinant pancreatic enzyme solution is used for digestion, the digestion time is 3 minutes, and the concentration of pancreatic enzyme in the recombinant pancreatic enzyme solution is 0.5-2.5 g / L.
[0029] Specifically, the inoculation density in S4 is 3000-10000 cells / cm 2 .
[0030] Specifically, the culture conditions in S4 are culture in a 37°C, 5% CO2 incubator.
[0031] Example 1 This embodiment provides a method for preparing very small embryonic-like stem cells, which specifically includes the following steps: S1. Isolation of bone marrow mononuclear cells: S11. After extracting the mouse femur under sterile conditions, rinse the femur with PBS buffer solution to obtain bone marrow stock solution, and take 5 mL of bone marrow stock solution and mix it with 5 mL of sodium heparin; S12. Filter the cells using a 50 μm cell strainer and centrifuge at 1400-600 rpm for 10 min at 4°C; S13. Remove the supernatant, take the cell pellet and add 8 mL of Lymphoprep separation solution to a 15 mL sterile centrifuge tube, mix, aspirate the middle white layer rich in mononuclear cells, and then add red blood cell lysis solution at a volume ratio of 1:5. After lysis on ice for 5 minutes, add 20 mL of PBS to terminate the reaction; S14. Centrifuge again at 4°C at a speed of 1400-600 rpm for 15 min, discard the supernatant, add PBS buffer containing 2 mM EDTA and 3% FBS to the precipitate, and add to 350 μL to resuspend the cells.
[0032] S2. Mononuclear cell labeling and SMES sorting: S21. The bone marrow mononuclear cell solution obtained in S14 was resuspended in a buffer solution, and FCS with a concentration of 10% was added. The bone marrow mononuclear cells and FCS were mixed for 20 minutes under an ice bath to maintain the optimal state of the cells, and then centrifuged at 1600 rpm for 10 minutes at 4°C, and the supernatant was removed; S22. Resuspend and mix cells: After removing the supernatant, add PBS buffer containing 2% FCS and use a vortex oscillator to thoroughly mix the cells and buffer to ensure that the cells are evenly distributed; Antibody labeling: prepare 6 Falcon tubes, including 1 isotype control staining tube, 4 single staining tubes, and 1 sorting cell tube; Three fluorescently labeled antibodies were added to the sorting cell tube: PE-labeled Lineage antibody mixture, PE-Cy5-labeled CD45 monoclonal antibody and FITC-labeled Sca-1 monoclonal antibody; three corresponding isotype control antibodies were added to the isotype control staining tube; the four single staining tubes were as follows: the first single staining tube was added with PE-labeled Lineage antibody mixture and the other two isotype control antibodies; the second single staining tube was added with PE-Cy5-labeled CD45 monoclonal antibody and the other two isotype control antibodies; the third single staining tube was added with FITC-labeled Sca-1 monoclonal antibody and the other two isotype control antibodies; the fourth single staining tube was added with another fluorescently labeled antibody (APC-labeled antibody) and the other two isotype control antibodies.
[0033] Mixing and incubation: Use a vortex oscillator to thoroughly mix the cell and antibody mixture in each tube, and incubate in an ice bath in the dark for 15 minutes to ensure that the antibody is fully bound to the cell surface marker.
[0034] S23. Washing and centrifugation: Wash with 2% FCS / PBS containing 2 mM EDTA to remove unbound antibodies, then centrifuge at 1400-600 rpm at 4°C and remove the supernatant; Cell resuspension: Resuspend cells in 2% FCS / PBS in preparation for sorting; Cell sorting: Moflo XDP cell sorter, set Lin - Sca-1 + CD45 - The cell population is very small embryonic stem cells.
[0035] S3. In vitro culture and passaging: S31. Inoculate the sorted VSELs into a T225 culture flask, add 15 mL of complete culture medium, and culture the cells at 37°C and 5% CO2 until the cells cover 85% of the surface of the culture flask. Use 0.25 g / L recombinant trypsin solution to digest the cells, ensuring that the cells are completely detached from the surface of the culture flask. Add fresh complete culture medium to terminate the digestion process, and then collect the digested cells by centrifugation (4°C, centrifugal speed of 1400-600 rpm, 5 min). Remove the digestion solution, resuspend the collected cells in new complete culture medium, and inoculate the cell resuspension into a new culture flask to obtain the initially expanded cells, called P0 cells.
[0036] S4. 8000 pieces / cm 2 The seeding density will be 1×10 7 P0 cells were inoculated into T175 culture flasks, 24 mL of complete culture medium was added, and the cells were cultured at 37°C and 5% CO2. The culture medium was changed every 2 days during the culture process until the cell fusion rate reached 90%. The cells were digested with 0.25 g / L recombinant trypsin solution, and fresh complete culture medium was added to terminate the digestion process. The cells were collected by centrifugation (4°C, centrifugal speed of 1400-600 rpm, 5 min), and then inoculated into new culture flasks to obtain further expanded cells, which were called P1 generation very small embryonic-like stem cells.
[0037] Example 2 This embodiment provides a method for preparing very small embryonic-like stem cells, which specifically includes the following steps: S1. Isolation of bone marrow mononuclear cells: S11. After extracting the mouse femur under sterile conditions, rinse the femur with PBS buffer solution to obtain bone marrow stock solution, and take 5 mL of bone marrow stock solution and mix it with 5 mL of sodium heparin; S12. Filter the cells using a 50 μm cell strainer and centrifuge at 1400-600 rpm for 10 min at 4°C; S13. Remove the supernatant, take the cell pellet and add 8 mL of Lymphoprep separation solution to a 15 mL sterile centrifuge tube, mix, aspirate the middle white layer rich in mononuclear cells, and then add red blood cell lysis solution at a volume ratio of 1:5. After lysis on ice for 5 minutes, add 20 mL of PBS to terminate the reaction; S14. Centrifuge again at 4°C at a speed of 1400-600 rpm for 15 min, discard the supernatant, add PBS buffer containing 2 mM EDTA and 3% FBS to the precipitate, and add to 350 μL to resuspend the cells.
[0038] S2. Mononuclear cell labeling and SMES sorting: S21. The bone marrow mononuclear cell solution obtained in S14 was resuspended in a buffer solution, and FCS with a concentration of 10% was added. The bone marrow mononuclear cells and FCS were mixed for 20 minutes under an ice bath to maintain the optimal state of the cells, and then centrifuged at 1600 rpm for 10 minutes at 4°C, and the supernatant was removed; S22. Resuspend and mix cells: After removing the supernatant, add PBS buffer containing 2% FCS and use a vortex oscillator to thoroughly mix the cells and buffer to ensure that the cells are evenly distributed; Antibody labeling: prepare 6 Falcon tubes, including 1 isotype control staining tube, 4 single staining tubes, and 1 sorting cell tube; Three fluorescently labeled antibodies were added to the sorting cell tube: PE-labeled Lineage antibody mixture, PE-Cy5-labeled CD45 monoclonal antibody and FITC-labeled Sca-1 monoclonal antibody; three corresponding isotype control antibodies were added to the isotype control staining tube; the four single staining tubes were as follows: the first single staining tube was added with PE-labeled Lineage antibody mixture and the other two isotype control antibodies; the second single staining tube was added with PE-Cy5-labeled CD45 monoclonal antibody and the other two isotype control antibodies; the third single staining tube was added with FITC-labeled Sca-1 monoclonal antibody and the other two isotype control antibodies; the fourth single staining tube was added with another fluorescently labeled antibody (APC-labeled antibody) and the other two isotype control antibodies.
[0039] Mixing and incubation: Use a vortex oscillator to thoroughly mix the cell and antibody mixture in each tube, and incubate in an ice bath in the dark for 15 minutes to ensure that the antibody is fully bound to the cell surface marker.
[0040] S23. Washing and centrifugation: Wash with 2% FCS / PBS containing 2 mM EDTA to remove unbound antibodies, then centrifuge at 1400-600 rpm at 4°C and remove the supernatant; Cell resuspension: Resuspend cells in 2% FCS / PBS in preparation for sorting; Cell sorting: Moflo XDP cell sorter, set Lin - Sca-1 + CD45 - The cell population is very small embryonic stem cells.
[0041] S3. In vitro culture and passaging: S31. Inoculate the sorted VSELs into a T225 culture flask, add 10 mL of complete culture medium, and culture the cells at 37°C and 5% CO2 until the cells cover 85% of the surface of the culture flask. Use 0.25 g / L recombinant trypsin solution to digest the cells, ensuring that the cells are completely detached from the surface of the culture flask. Add fresh complete culture medium to terminate the digestion process, and then collect the digested cells by centrifugation (4°C, centrifugal speed of 1400-600 rpm, 5 min). Remove the digestion solution, resuspend the collected cells in new complete culture medium, and inoculate the cell resuspension into a new culture flask to obtain the initially expanded cells, called P0 cells.
[0042] S4. 8000 pieces / cm 2 The seeding density will be 1×10 7 P0 cells were inoculated into T175 culture flasks, 22 mL of complete culture medium was added, and the cells were cultured at 37°C and 5% CO2. The culture medium was changed every 2 days during the culture process until the cell fusion rate reached 90%. The cells were digested with 0.25 g / L recombinant trypsin solution, and fresh complete culture medium was added to terminate the digestion process. The cells were collected by centrifugation (4°C, centrifugal speed of 1400-600 rpm, 5 min), and then inoculated into new culture flasks to obtain further expanded cells, which were called P1 generation very small embryonic-like stem cells.
[0043] Example 3 This embodiment provides a method for preparing very small embryonic-like stem cells, which specifically includes the following steps: S1. Isolation of bone marrow mononuclear cells: S11. After extracting the mouse femur under sterile conditions, rinse the femur with PBS buffer solution to obtain bone marrow stock solution, and take 5 mL of bone marrow stock solution and mix it with 5 mL of sodium heparin; S12. Filter the cells using a 50 μm cell strainer and centrifuge at 1400-600 rpm for 10 min at 4°C; S13. Remove the supernatant, take the cell pellet and add 8 mL of Lymphoprep separation solution to a 15 mL sterile centrifuge tube, mix, aspirate the middle white layer rich in mononuclear cells, and then add red blood cell lysis solution at a volume ratio of 1:5. After lysis on ice for 5 minutes, add 20 mL of PBS to terminate the reaction; S14. Centrifuge again at 4°C at a speed of 1400-600 rpm for 15 min, discard the supernatant, add PBS buffer containing 2 mM EDTA and 3% FBS to the precipitate, and add to 350 μL to resuspend the cells.
[0044] S2. Mononuclear cell labeling and SMES sorting: S21. The bone marrow mononuclear cell solution obtained in S14 was resuspended in a buffer solution, and FCS with a concentration of 10% was added. The bone marrow mononuclear cells and FCS were mixed for 20 minutes under an ice bath to maintain the optimal state of the cells, and then centrifuged at 1600 rpm for 10 minutes at 4°C, and the supernatant was removed; S22. Resuspend and mix cells: After removing the supernatant, add PBS buffer containing 2% FCS and use a vortex oscillator to thoroughly mix the cells and buffer to ensure that the cells are evenly distributed; Antibody labeling: prepare 6 Falcon tubes, including 1 isotype control staining tube, 4 single staining tubes, and 1 sorting cell tube; Three fluorescently labeled antibodies were added to the sorting cell tube: PE-labeled Lineage antibody mixture, PE-Cy5-labeled CD45 monoclonal antibody and FITC-labeled Sca-1 monoclonal antibody; three corresponding isotype control antibodies were added to the isotype control staining tube; the four single staining tubes were as follows: the first single staining tube was added with PE-labeled Lineage antibody mixture and the other two isotype control antibodies; the second single staining tube was added with PE-Cy5-labeled CD45 monoclonal antibody and the other two isotype control antibodies; the third single staining tube was added with FITC-labeled Sca-1 monoclonal antibody and the other two isotype control antibodies; the fourth single staining tube was added with another fluorescently labeled antibody (APC-labeled antibody) and the other two isotype control antibodies.
[0045] Mixing and incubation: Use a vortex oscillator to thoroughly mix the cell and antibody mixture in each tube, and incubate in an ice bath in the dark for 15 minutes to ensure that the antibody is fully bound to the cell surface marker.
[0046] S23. Washing and centrifugation: Wash with 2% FCS / PBS containing 2 mM EDTA to remove unbound antibodies, then centrifuge at 1400-600 rpm at 4°C and remove the supernatant; Cell resuspension: Resuspend cells in 2% FCS / PBS in preparation for sorting; Cell sorting: Moflo XDP cell sorter, set Lin - Sca-1 + CD45 - The cell population is very small embryonic stem cells.
[0047] S3. In vitro culture and passaging: S31. Inoculate the sorted VSELs into a T225 culture flask, add 8 mL of complete culture medium, and culture the cells at 37°C and 5% CO2 until the cells cover 85% of the surface of the culture flask. Use 0.25 g / L recombinant trypsin solution to digest the cells, ensuring that the cells are completely detached from the surface of the culture flask. Add fresh complete culture medium to terminate the digestion process, and then collect the digested cells by centrifugation (4°C, centrifugal speed of 1400-600 rpm, 5 min). Remove the digestion solution, resuspend the collected cells in new complete culture medium, and inoculate the cell resuspension into a new culture flask to obtain the initially expanded cells, which are called P0 cells.
[0048] S4. 8000 pieces / cm 2 The seeding density will be 1×10 7 P0 cells were inoculated into T175 culture flasks, 20 mL of complete culture medium was added, and the cells were cultured at 37°C and 5% CO2. The culture medium was changed every 2 days during the culture process until the cell fusion rate reached 90%. The cells were digested with 0.25 g / L recombinant trypsin solution, and fresh complete culture medium was added to terminate the digestion process. The cells were collected by centrifugation (4°C, centrifugal speed of 1400-600 rpm, 5 min), and then inoculated into new culture flasks to obtain further expanded cells, which were called P1 generation very small embryonic-like stem cells.
[0049] Example 4 This embodiment provides a method for preparing very small embryonic-like stem cells, which specifically includes the following steps: S1. Isolation of bone marrow mononuclear cells: S11. After extracting the mouse femur under sterile conditions, rinse the femur with PBS buffer solution to obtain bone marrow stock solution, and take 5 mL of bone marrow stock solution and mix it with 5 mL of sodium heparin; S12. Filter the cells using a 50 μm cell strainer and centrifuge at 1400-600 rpm for 10 min at 4°C; S13. Remove the supernatant, take the cell pellet and add 8 mL of Lymphoprep separation solution to a 15 mL sterile centrifuge tube, mix, aspirate the middle white layer rich in mononuclear cells, and then add red blood cell lysis solution at a volume ratio of 1:5. After lysis on ice for 5 minutes, add 20 mL of PBS to terminate the reaction; S14. Centrifuge again at 4°C at a speed of 1400-600 rpm for 15 min, discard the supernatant, add PBS buffer containing 2 mM EDTA and 3% FBS to the precipitate, and add to 350 μL to resuspend the cells.
[0050] S2. Mononuclear cell labeling and SMES sorting: S21. The bone marrow mononuclear cell solution obtained in S14 was resuspended in a buffer solution, and FCS with a concentration of 10% was added. The bone marrow mononuclear cells and FCS were mixed for 20 minutes under an ice bath to maintain the optimal state of the cells, and then centrifuged at 1600 rpm for 10 minutes at 4°C, and the supernatant was removed; S22. Resuspend and mix cells: After removing the supernatant, add PBS buffer containing 2% FCS and use a vortex oscillator to thoroughly mix the cells and buffer to ensure that the cells are evenly distributed; Antibody labeling: prepare 6 Falcon tubes, including 1 isotype control staining tube, 4 single staining tubes, and 1 sorting cell tube; Three fluorescently labeled antibodies were added to the sorting cell tube: PE-labeled Lineage antibody mixture, PE-Cy5-labeled CD45 monoclonal antibody and FITC-labeled Sca-1 monoclonal antibody; three corresponding isotype control antibodies were added to the isotype control staining tube; the four single staining tubes were as follows: the first single staining tube was added with PE-labeled Lineage antibody mixture and the other two isotype control antibodies; the second single staining tube was added with PE-Cy5-labeled CD45 monoclonal antibody and the other two isotype control antibodies; the third single staining tube was added with FITC-labeled Sca-1 monoclonal antibody and the other two isotype control antibodies; the fourth single staining tube was added with another fluorescently labeled antibody (APC-labeled antibody) and the other two isotype control antibodies.
[0051] Mixing and incubation: Use a vortex oscillator to thoroughly mix the cell and antibody mixture in each tube, and incubate in an ice bath in the dark for 15 minutes to ensure that the antibody is fully bound to the cell surface marker.
[0052] S23. Washing and centrifugation: Wash with 2% FCS / PBS containing 2 mM EDTA to remove unbound antibodies, then centrifuge at 1400-600 rpm at 4°C and remove the supernatant; Cell resuspension: Resuspend cells in 2% FCS / PBS in preparation for sorting; Cell sorting: Moflo XDP cell sorter, set Lin - Sca-1 + CD45 - The cell population is very small embryonic stem cells.
[0053] S3. In vitro culture and passaging: S31. Inoculate the sorted VSELs into a T225 culture flask, add 5 mL of complete culture medium, and culture the cells at 37°C and 5% CO2 until the cells cover 85% of the surface of the culture flask. Use 0.25 g / L recombinant trypsin solution to digest the cells, ensuring that the cells are completely detached from the surface of the culture flask. Add fresh complete culture medium to terminate the digestion process, and then collect the digested cells by centrifugation (4°C, centrifugal speed of 1400-600 rpm, 5 min). Remove the digestion solution, resuspend the collected cells in new complete culture medium, and inoculate the cell resuspension into a new culture flask to obtain the initially expanded cells, which are called P0 cells.
[0054] S4. 8000 pieces / cm 2 The seeding density will be 1×10 7 P0 cells were inoculated into T175 culture flasks, 18 mL of complete culture medium was added, and the cells were cultured at 37°C and 5% CO2. The culture medium was changed every 2 days during the culture process until the cell fusion rate reached 90%. The cells were digested with 0.25 g / L recombinant trypsin solution, and fresh complete culture medium was added to terminate the digestion process. The cells were collected by centrifugation (4°C, centrifugal speed of 1400-600 rpm, 5 min), and then inoculated into new culture flasks to obtain further expanded cells, which were called P1 generation very small embryonic-like stem cells.
[0055] Example 5 This embodiment provides a method for preparing very small embryonic-like stem cells, which specifically includes the following steps: S1. Isolation of bone marrow mononuclear cells: S11. After extracting the mouse femur under sterile conditions, rinse the femur with PBS buffer solution to obtain bone marrow stock solution, and take 5 mL of bone marrow stock solution and mix it with 5 mL of sodium heparin; S12. Filter the cells using a 50 μm cell strainer and centrifuge at 1400-600 rpm for 10 min at 4°C; S13. Remove the supernatant, take the cell pellet and add 8 mL of Lymphoprep separation solution to a 15 mL sterile centrifuge tube, mix, aspirate the middle white layer rich in mononuclear cells, and then add red blood cell lysis solution at a volume ratio of 1:5. After lysis on ice for 5 minutes, add 20 mL of PBS to terminate the reaction; S14. Centrifuge again at 4°C at a speed of 1400-600 rpm for 15 min, discard the supernatant, add PBS buffer containing 2 mM EDTA and 3% FBS to the precipitate, and add to 350 μL to resuspend the cells.
[0056] S2. Mononuclear cell labeling and SMES sorting: S21. The bone marrow mononuclear cell solution obtained in S14 was resuspended in a buffer solution, and FCS with a concentration of 10% was added. The bone marrow mononuclear cells and FCS were mixed for 20 minutes under an ice bath to maintain the optimal state of the cells, and then centrifuged at 1600 rpm for 10 minutes at 4°C, and the supernatant was removed; S22. Resuspend and mix cells: After removing the supernatant, add PBS buffer containing 2% FCS and use a vortex oscillator to thoroughly mix the cells and buffer to ensure that the cells are evenly distributed; Antibody labeling: prepare 6 Falcon tubes, including 1 isotype control staining tube, 4 single staining tubes, and 1 sorting cell tube; Three fluorescently labeled antibodies were added to the sorting cell tube: PE-labeled Lineage antibody mixture, PE-Cy5-labeled CD45 monoclonal antibody and FITC-labeled Sca-1 monoclonal antibody; three corresponding isotype control antibodies were added to the isotype control staining tube; the four single staining tubes were as follows: the first single staining tube was added with PE-labeled Lineage antibody mixture and the other two isotype control antibodies; the second single staining tube was added with PE-Cy5-labeled CD45 monoclonal antibody and the other two isotype control antibodies; the third single staining tube was added with FITC-labeled Sca-1 monoclonal antibody and the other two isotype control antibodies; the fourth single staining tube was added with another fluorescently labeled antibody (APC-labeled antibody) and the other two isotype control antibodies.
[0057] Mixing and incubation: Use a vortex oscillator to thoroughly mix the cell and antibody mixture in each tube, and incubate in an ice bath in the dark for 15 minutes to ensure that the antibody is fully bound to the cell surface marker.
[0058] S23. Washing and centrifugation: Wash with 2% FCS / PBS containing 2 mM EDTA to remove unbound antibodies, then centrifuge at 1400-600 rpm at 4°C and remove the supernatant; Cell resuspension: Resuspend cells in 2% FCS / PBS in preparation for sorting; Cell sorting: Moflo XDP cell sorter, set Lin - Sca-1 + CD45 - The cell population is very small embryonic stem cells.
[0059] S3. In vitro culture and passaging: S31. Inoculate the sorted VSELs into a T225 culture flask, add 5 mL of complete culture medium, and culture the cells at 37°C and 5% CO2 until the cells cover 85% of the surface of the culture flask. Use 0.25 g / L recombinant trypsin solution to digest the cells, ensuring that the cells are completely detached from the surface of the culture flask. Add fresh complete culture medium to terminate the digestion process, and then collect the digested cells by centrifugation (4°C, centrifugal speed of 1400-600 rpm, 5 min). Remove the digestion solution, resuspend the collected cells in new complete culture medium, and inoculate the cell resuspension into a new culture flask to obtain the initially expanded cells, which are called P0 cells.
[0060] S4. 5000 pieces / cm 2 The seeding density will be 1×10 7 P0 cells were inoculated into T175 culture flasks, 18 mL of complete culture medium was added, and the cells were cultured at 37°C and 5% CO2. The culture medium was changed every 2 days during the culture process until the cell fusion rate reached 90%. The cells were digested with 0.25 g / L recombinant trypsin solution, and fresh complete culture medium was added to terminate the digestion process. The cells were collected by centrifugation (4°C, centrifugal speed of 1400-600 rpm, 5 min), and then inoculated into new culture flasks to obtain further expanded cells, which were called P1 generation very small embryonic-like stem cells.
[0061] Example 6 This embodiment provides a method for preparing very small embryonic-like stem cells, which specifically includes the following steps: S1. Isolation of bone marrow mononuclear cells: S11. After extracting the mouse femur under sterile conditions, rinse the femur with PBS buffer solution to obtain bone marrow stock solution, and take 5 mL of bone marrow stock solution and mix it with 5 mL of sodium heparin; S12. Filter the cells using a 50 μm cell strainer and centrifuge at 1400-600 rpm for 10 min at 4°C; S13. Remove the supernatant, take the cell pellet and add 8 mL of Lymphoprep separation solution to a 15 mL sterile centrifuge tube, mix, aspirate the middle white layer rich in mononuclear cells, and then add red blood cell lysis solution at a volume ratio of 1:5. After lysis on ice for 5 minutes, add 20 mL of PBS to terminate the reaction; S14. Centrifuge again at 4°C at a speed of 1400-600 rpm for 15 min, discard the supernatant, add PBS buffer containing 2 mM EDTA and 3% FBS to the precipitate, and add to 350 μL to resuspend the cells.
[0062] S2. Mononuclear cell labeling and SMES sorting: S21. The bone marrow mononuclear cell solution obtained in S14 was resuspended in a buffer solution, and FCS with a concentration of 10% was added. The bone marrow mononuclear cells and FCS were mixed for 20 minutes under an ice bath to maintain the optimal state of the cells, and then centrifuged at 1600 rpm for 10 minutes at 4°C, and the supernatant was removed; S22. Resuspend and mix cells: After removing the supernatant, add PBS buffer containing 2% FCS and use a vortex oscillator to thoroughly mix the cells and buffer to ensure that the cells are evenly distributed; Antibody labeling: prepare 6 Falcon tubes, including 1 isotype control staining tube, 4 single staining tubes, and 1 sorting cell tube; Three fluorescently labeled antibodies were added to the sorting cell tube: PE-labeled Lineage antibody mixture, PE-Cy5-labeled CD45 monoclonal antibody and FITC-labeled Sca-1 monoclonal antibody; three corresponding isotype control antibodies were added to the isotype control staining tube; the four single staining tubes were as follows: the first single staining tube was added with PE-labeled Lineage antibody mixture and the other two isotype control antibodies; the second single staining tube was added with PE-Cy5-labeled CD45 monoclonal antibody and the other two isotype control antibodies; the third single staining tube was added with FITC-labeled Sca-1 monoclonal antibody and the other two isotype control antibodies; the fourth single staining tube was added with another fluorescently labeled antibody (APC-labeled antibody) and the other two isotype control antibodies.
[0063] Mixing and incubation: Use a vortex oscillator to thoroughly mix the cell and antibody mixture in each tube, and incubate in an ice bath in the dark for 15 minutes to ensure that the antibody is fully bound to the cell surface marker.
[0064] S23. Washing and centrifugation: Wash with 2% FCS / PBS containing 2 mM EDTA to remove unbound antibodies, then centrifuge at 1400-600 rpm at 4°C and remove the supernatant; Cell resuspension: Resuspend cells in 2% FCS / PBS in preparation for sorting; Cell sorting: Moflo XDP cell sorter, set Lin - Sca-1 + CD45 - The cell population is very small embryonic stem cells.
[0065] S3. In vitro culture and passaging: S31. Inoculate the sorted VSELs into a T225 culture flask, add 5 mL of complete culture medium, and culture the cells at 37°C and 5% CO2 until the cells cover 85% of the surface of the culture flask. Use 0.25 g / L recombinant trypsin solution to digest the cells, ensuring that the cells are completely detached from the surface of the culture flask. Add fresh complete culture medium to terminate the digestion process, and then collect the digested cells by centrifugation (4°C, centrifugal speed of 1400-600 rpm, 5 min). Remove the digestion solution, resuspend the collected cells in new complete culture medium, and inoculate the cell resuspension into a new culture flask to obtain the initially expanded cells, which are called P0 cells.
[0066] S4. 3000 pieces / cm 2 The seeding density will be 1×10 7 P0 cells were inoculated into T175 culture flasks, 18 mL of complete culture medium was added, and the cells were cultured at 37°C and 5% CO2. The culture medium was changed every 2 days during the culture process until the cell fusion rate reached 90%. The cells were digested with 0.25 g / L recombinant trypsin solution, and fresh complete culture medium was added to terminate the digestion process. The cells were collected by centrifugation (4°C, centrifugal speed of 1400-600 rpm, 5 min), and then inoculated into new culture flasks to obtain further expanded cells, which were called P1 generation very small embryonic-like stem cells.
[0067] Comparative Example 1 This example is a comparative example of Example 1, except that the complete culture medium is replaced by IMDM basal culture medium, and the other steps and parameters are the same as those of Example 1.
[0068] Comparative Example 2 This example is used as a comparative example of Example 1, except that the recombinant trypsin solution is replaced with ordinary trypsin, and the other steps and parameters are the same as those of Example 1.
[0069] The numbers of live cells and cell viability of the sELSCs obtained after digestion in Examples 1-6 and Comparative Examples 1-2 were counted, and the results are shown in Table 1.
[0070]
[0071] By analyzing the data in Table 1 for Examples 1-6 and Comparative Examples 1-2, the following conclusions can be drawn: 1. Examples 1-4 show that as the amount of complete culture medium decreases, the number of live cells decreases and the cell viability also decreases, which indicates that within the scope of the present application, the amount of complete culture medium used is positively correlated with the culture effect of VSELs, that is, the more complete culture medium is used, the higher the number of live cells and the cell viability.
[0072] 2. Examples 5-6 show that as the seeding density decreases, the number of live cells decreases significantly and the cell viability also decreases; this indicates that the seeding density has a significant effect on the culture effect of VSELs, and a higher seeding density helps to increase the number of live cells and cell viability.
[0073] 3. Comparative Example 1 shows that after the complete medium was replaced with IMDM basal medium, the number of live cells and cell viability decreased significantly, indicating that the complete medium has an important influence on the culture effect of VSELs, and the use of the complete medium can significantly increase the number of live cells and cell viability.
[0074] 4. Comparative Example 2 shows that after the recombinant trypsin solution was replaced with ordinary trypsin, the number of live cells and the cell viability were significantly reduced, indicating that the recombinant trypsin solution has advantages in the cell digestion process, and the use of the recombinant trypsin solution can obtain a higher number of live cells and cell viability.
[0075] By comparing the experimental results under different conditions, it is proved that the application optimizes the dosage of complete culture medium, inoculation density and selection of digestive enzymes. Complete culture medium can significantly increase the number of living cells and cell viability, and inoculation density and recombinant trypsin solution have a significant impact on the culture effect of VSELs, providing a scientific basis for the efficient preparation of VSELs.
[0076] Although the present invention has been described in detail above by general description and specific embodiments, it is obvious to those skilled in the art that some modifications or improvements can be made to the present invention. Therefore, these modifications or improvements made without departing from the spirit of the present invention all belong to the scope of protection claimed by the present invention.
Claims
1. A method for preparing very small embryonic-like stem cells, characterized in that: The following steps are involved: S1. Extract mouse femurs under sterile conditions and wash to obtain bone marrow stock solution, then filter, centrifuge, separate mononuclear cells, lyse red blood cells, centrifuge again and resuspend to obtain mononuclear cell suspension; S2. resuspending, labeling, incubating, washing and sorting the bone marrow mononuclear cell solution obtained in S1 to obtain SMEL stem cells; S3. The sorted VSELs were inoculated into T225 culture flasks, complete medium was added, and the cells were cultured until the cell confluence reached 85%, and then washed, digested, and digested. The cells after digestion were collected to obtain P0 VSELs. S4. The P0 generation VSEL stem cells are inoculated into a T225 culture flask, complete culture medium is added, and culture is continued. During the culture process, the medium is changed every 2 days until the cell fusion rate reaches 90%, and then the P1 generation VSEL stem cells are obtained.
2. The method for preparing very small embryonic-like stem cells according to claim 1, characterized in that: The complete culture medium uses DMEM-F12 culture medium as the base liquid, and includes the following components in the following concentrations: Epidermal growth factor 1ng / mL, ActivinA 1ng / mL, transforming growth factor β 2ng / mL, transforming growth factor α ng / mL, vascular endothelial growth factor 2ng / mL, basic fibroblast growth factor 50ng / mL, MEK inhibitor 0.1μM, GSK-3 inhibitor 30μM, leukemia inhibitory factor 3ng / mL, ALK-5 inhibitor A83-01 50μM, dasatinib 0.001μM, interleukin-1β 10ng / mL, interleukin-6 ng / mL, fibronectin 5mg / L, laminin 3mg / L, transferrin 5mg / L, sodium bicarbonate 2.5g / L, estradiol 3ng / mL, human serum albumin 20ng / mL, insulin 5mg / L, L-glutamine 285.3mg / L, α-D-glucose 3135mg / L, vitamin C 80mg / L, CuSO4 20ng / mL, ZnSO4100ng / mL, Na2SeO3 0.01ng / mL, FeCl3 200ng / mL, Na2SiO3 100ng / mL, MnSO4 20ng / mL, CoCl220ng / mL.
3. The method for preparing very small embryonic-like stem cells according to claim 1, characterized in that: The separation of S1 bone marrow mononuclear cells includes the following specific steps: S11. After extracting the mouse femur under sterile conditions, the femur was rinsed with PBS buffer solution to obtain bone marrow stock solution, and the bone marrow stock solution was mixed with heparin saline; S12. Filter the cells using a 50 μm filter and centrifuge at 1400-600 rpm for 5-10 min at 4°C; S13. Remove the supernatant, mix the cell pellet with Lymphoprep separation solution, aspirate the middle white layer rich in mononuclear cells, add red blood cell lysis solution at a volume ratio of 1:5, lyse for 3-5 minutes in an ice bath, and then add 20mL PBS to terminate the reaction; S14. Centrifuge again at 4°C at a speed of 1400-600 rpm for 5-20 min, discard the supernatant, and add PBS containing 2 mM EDTA and 3% FBS to the precipitate to make up to 350 μL to resuspend the cells.
4. The method for preparing very small embryonic-like stem cells according to claim 1, characterized in that: In S2, the specific steps of mononuclear cell labeling and VSEL stem cell sorting are as follows: S21. The bone marrow mononuclear cell solution obtained in S14 was resuspended in a buffer solution, and 10% FCS was added. The suspension was placed in an ice bath for 20 min, and then centrifuged at 4°C at a speed of 1400-600 rpm for 5-20 min. S22. Discard the supernatant, add buffer, mix thoroughly, and prepare 6 Falcon tubes, including 1 isotype control staining tube, 4 single staining tubes, and 1 cell sorting tube; Three fluorescently labeled antibodies were added to the sorting cell tube: PE-labeled Lineage antibody mixture, PE-Cy5-labeled CD45 monoclonal antibody, and FITC-labeled Sca-1 monoclonal antibody; three corresponding isotype control antibodies were added to the isotype control staining tube; The 4 single staining tubes are: the first single staining tube is added with PE-labeled Lineage antibody mixture and the other two isotype control antibodies; the second single staining tube is added with PE-Cy5-labeled CD45 monoclonal antibody and the other two isotype control antibodies; the third single staining tube is added with FITC-labeled Sca-1 monoclonal antibody and the other two isotype control antibodies; the fourth single staining tube is added with APC-labeled fluorescent labeled antibody and the other two isotype control antibodies; Mix thoroughly by vortexing and incubate in an ice bath in the dark for 15 min; S23. Wash with 2% FCS / PBS containing 2 mM EDTA, centrifuge, remove the supernatant, resuspend in 2% FCS / PBS, sort on MofloXDP cell sorter, set Lin - Sca-1 + CD45 - The cell population is very small embryonic stem cells.
5. The method for preparing very small embryonic-like stem cells according to claim 3, characterized in that: The heparin sodium concentration of the heparin saline is 3000-10000 U / mL; the volume ratio of the bone marrow stock solution to the heparin saline is 3:2-9.
6. The method for preparing very small embryonic-like stem cells according to claim 3, characterized in that: The density of the Lymphoprep separation solution is 1.077 g / mL, and the volume ratio of the cell precipitation to the Lymphoprep separation solution is 1:1-5.
7. The method for preparing very small embryonic-like stem cells according to claim 1, characterized in that: The complete culture medium is added to the S3 in an amount of 5-15 mL, and the complete culture medium is added to the S4 in an amount of 18-24 mL.
8. The method for preparing very small embryonic-like stem cells according to claim 1, characterized in that: In S3, a recombinant pancreatic enzyme solution is used for digestion, the digestion time is 3 minutes, and the concentration of pancreatic enzyme in the recombinant pancreatic enzyme solution is 0.25-2.5 g / L.
9. The method for preparing very small embryonic-like stem cells according to claim 1, characterized in that: The inoculation density in S4 is 3000-10000 cells / cm 2 .
10. The method for preparing very small embryonic-like stem cells according to claim 1, characterized in that: The culture conditions in S4 are to culture in a 37° C., 5% CO 2 incubator.
Citation Information
Cited By
Culture medium and culture method for adipose-derived minimal embryonic-like stem cells and application of adipose-derived minimal embryonic-like stem cells
CN119955716A
A culture medium, culture method and application for adipose-derived very small embryonic-like stem cells
CN119955716B
